Clinical Trial: A Study to Learn About How Safe BAY 3389934 Is, Its Suitable Dose, and How It Affects the Participants with Sepsis Induced Coagulopathy

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06854640) titled 'A Study to Learn About How Safe BAY 3389934 Is, Its Suitable Dose, and How It Affects the Participants with Sepsis Induced Coagulopathy' on Feb. 28.

Brief Summary: Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.

Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels...